Q4 2025 Ambu A/S Earnings Call Transcript
Key Points
- Ambu AS (AMBFF) reported a strong organic revenue growth of 13.1% for the year, with the endoscopy business growing by 15.4%.
- The company achieved a positive cash flow of DKK407 million for the year.
- Ambu AS (AMBFF) launched its next-era strategy, aiming for global endoscopy leadership, which reflects its progress and future ambitions.
- The company is seeing solid double-digit growth in its respiratory segment, driven by bronchoscopy solutions and the newly launched video laryngoscope solution, SureSight.
- Ambu AS (AMBFF) has a strong focus on innovation and customer-centricity, aiming to advance its software and AI solutions to support endoscopy procedures.
- The EBIT margin before special items was 13.0%, impacted negatively by FX and tariffs.
- The company experienced lower growth in its anesthesia and patient monitoring segment in Q4, with a growth rate of 6.4%.
- There was a significant decline in growth in the ENT segment during Q4, affecting overall performance.
- Ambu AS (AMBFF) faces challenges from increased global tariffs, impacting its financial results.
- The company anticipates a back-end loaded year for growth and margins, with potential lower growth in Q1 due to high comparables from the previous year.
/- -
Hello, everyone, and welcome to this conference call presenting our Q4 and full year results from 2024, '25 for Ambu. My name is Britt Meelby Jensen. I'm the CEO of Ambu. And with me today, I have Henrik Skak Bender, our Chief Financial Officer. So let's get going.
So we'll start with the highlights from the year that we just exited. And overall, we delivered a very strong organic revenue growth of 13.1% and if we look at our endoscopy business, that grew for the year, 15.4%. This underscores the continued momentum and potential of moving patients from using reusable endoscopes to single-use endoscopes.
If we look at our margins, we delivered a margin of 13.0% for the year, and this is impacted positively by our operational leverage where we continue to drive scale and be more efficient.
And then on the other side, we also -- given we are a growth company as the most important, we are, as we have previously communicated, continuing to invest in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
